National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 1) (No. PB 3 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00046

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 3 of 2013
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 1)
 
National Health Act 1953
___________________________________________________________________________
 
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated    9 January 2013
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 1).
 
(2)                This Instrument may also be cited as PB 3 of 2013.
 
2             Commencement
                This Instrument commences on 1 February 2013.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]    Schedule 1 Part 1, entry for Fludarabine in the form Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL:
substitute:
 
 
Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL
Injection
AS-Fludarabine
YA
MP
C3887
PB

 
 
 
Fludarabine Ebewe
SZ
MP
C3887
PB

 
 
 
 
 
 
 

[2]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection:
substitute:
 
Gemcitabine
Powder for I.V. infusion 1 g (as hydrochloride)
Injection
AS-Gemcitabine
YA
MP
 
D
 

 
 
 
DBL Gemcitabine for Injection
HH
MP
 
D
 
[3]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection:
substitute:
 
 
Powder for I.V. infusion 2 g (as hydrochloride)
Injection
AS-Gemcitabine
YA
MP
 
D

 
 
 
DBL Gemcitabine for Injection
HH
MP
 
D

 
[4]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection:
substitute:
 
 
Powder for I.V. infusion 200 mg (as hydrochloride)
Injection
AS-Gemcitabine
YA
MP
 
D

 
 
 
DBL Gemcitabine for Injection
HH
MP
 
D
 
 
[5]    Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL with manner of administration Injection and brand DBL Oxaliplatin Concentrate:
substitute:
 
 
Solution concentrate for I.V. infusion 100 mg in 20 mL
Injection
AS-Oxaliplatin
YA
MP
C3900 C3901 C3930 C3939
D

 
 
 
DBL Oxaliplatin Concentrate
HH
MP
C3900 C3901 C3930 C3939
D

 
[6]    Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 200 mg in 40 mL with manner of administration Injection and brand Eloxatin:
substitute:
 
 
Solution concentrate for I.V. infusion 200 mg in 40 mL
Injection
AS-Oxaliplatin
YA
MP
C3900 C3901 C3930 C3939
 
D

 
 
 
Eloxatin
SW
MP
C3900 C3901 C3930 C3939
 
D

[7]    Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL with manner of administration Injection and brand DBL Oxaliplatin Concentrate:
substitute:
 
 
Solution concentrate for I.V. infusion 50 mg in 10 mL
Injection
AS-Oxaliplatin
YA
MP
C3900 C3901 C3930 C3939
 
D

 
 
 
DBL Oxaliplatin Concentrate
HH
MP
C3900 C3901 C3930 C3939
 
D

[8]    Schedule 1 Part 1, after entry for Paclitaxel in the form Solution concentrate for I.V. infusion 100 mg in 16.7 mL with manner of administration Injection and brand Anzatax:
insert:
 
GN-Paclitaxel
YA
MP
C3186 C3890 C3902 C3917 C3955
C3956
 
D
[9]    Schedule 1 Part 1, after entry for Paclitaxel in the form Solution concentrate for I.V. infusion 30 mg in 5 mL with manner of administration Injection and brand Anzatax:
insert:
 
GN-Paclitaxel
YA
MP
C3186 C3890 C3902 C3917 C3955
C3956
 
D
[10]  Schedule 1 Part 1, after entry for Paclitaxel in the form Solution concentrate for I.V. infusion 300 mg in 50 mL with manner of administration Injection and brand Anzatax:
insert:
 
GN-Paclitaxel
YA
MP
C3186 C3890 C3902 C3917 C3955
C3956
 
D
[11]  Schedule 1 Part 1, after entry for Topotecan in the form Powder for I.V. infusion 4 mg (as hydrochloride) with manner of administration Injection and brand Hycamtin:
insert:
 
Topotecan Agila
YA
MP
C3186
D
 
[12]  Schedule 1 Part 1, entry for Vinorelbine in the form Solution for I.V. infusion 10 mg (as tartrate) in 1 mL with manner of administration Injection and brand Hospira Pty Limited:
substitute:
 
Vinorelbine
Solution for I.V. infusion 10 mg (as tartrate) in 1 mL
Injection
AS-Vinorelbine
YA
MP
C3890
C3907
 
PB

 
 
 
Hospira Pty Limited
HH
MP
C3890
C3907
 
PB

[13]  Schedule 1 Part 1, entry for Vinorelbine in the form Solution for I.V. infusion 50 mg (as tartrate) in 5 mL with manner of administration Injection and brand Hospira Pty Limited:
substitute:
 
 
Solution for I.V. infusion 50 mg (as tartrate) in 5 mL
Injection
AS-Vinorelbine
YA
MP
C3890
C3907
 
PB

 
 
 
Hospira Pty Limited
HH
MP
C3890
C3907
 
PB

[14]  Schedule 3, after the entry for WQ:
insert:
 
YA
Agila Australasia Pty Ltd
 12 154 055 339
 
 
 
 
 
 
 
 
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.comlaw.gov.au.